98%
921
2 minutes
20
Introduction: Stent under-expansion due to calcification is associated with a less durable result. The development of intravascular lithotripsy (IVL) has provided clinicians with a readily available, simple-to-use treatment option for coronary calcification, but the use of IVL within a previously stented segment is currently off-license. There are, however, developing data suggesting that the use of IVL can be an effective treatment option for patients with calcific stent under-expansion.
Method: This was a single-center study of all patients treated with IVL for calcific stent under-expansion between January 2019 and June 2021. The impact of IVL on quantitative coronary angiography (QCA) stenosis and on the minimal stent area (MSA) derived from intracoronary imaging were recorded. The presence of periprocedural complications and adverse cardiovascular events was obtained from the clinical record during the study timeframe.
Results: Thirty-nine patients underwent IVL for calcific stent under-expansion during the study time frame with one patient treated with more than one lesion in the same session. In all lesions, there was an improvement in the QCA stenosis with 37 (92.5%) having a residual stenosis of ≤30%. The mean QCA stenosis pre-IVL was 68 ± 21% and following IVL the mean QCA was 18 ± 9% (p < 0.001). In all lesions, there was an improvement in the MSA, with 26 (92.9%) achieving an MSA of more than 4.5 mm. The mean MSA pre-IVL was 3.88 ± 1.51 mm and following IVL the mean MSA was 7.41 ± 2.34 mm (p < 0.001). There were no major procedural complications. Over a mean follow-up of 506 ± 277 days, one patient died from ventricular arrhythmia but there were no other major adverse cardiovascular events.
Conclusion: This single-center study demonstrates that IVL is a safe and effective treatment for calcific stent under-expansion with good medium-term results.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ccd.30516 | DOI Listing |
Front Cardiovasc Med
July 2025
Department of Cardiology, Affiliated Hospital of Hebei University, Baoding, China.
Background: Acute stent thrombosis (AST) is a rare but serious complication occurring within 24 h after percutaneous coronary intervention (PCI), typically caused by insufficient antiplatelet therapy, stent under-expansion, or malapposition. Tissue prolapse (TP) within the stent is less frequently reported as a cause of AST and lacks direct imaging-based evidence.
Case Summary: We report a case of a patient with acute ST-segment elevation myocardial infarction (STEMI) who experienced recurrent ST-segment elevation 1 h after primary PCI.
Eur Heart J Cardiovasc Imaging
July 2025
Rigshospitalet, Copenhagen, Denmark.
Aims: To evaluate stent frame expansion and ellipticity of the Evolut™ transcatheter heart valve (THV) and its subsequent impact on valve performance in patients with bicuspid aortic stenosis (AS) using pre- and post-procedural cardiac computed tomography (CT). In transcatheter aortic valve implantation (TAVI) for native bicuspid AS, concerns arise regarding the risk for reduced stent frame expansion and increased ellipticity compared with valves implanted in tricuspid AS. The implications of stent frame under-expansion and eccentricity on THV performance remain unclear.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
September 2025
Laboratory and Cardiovascular Interventional Unit Umberto Primo Hospital, Division of Cardiology Catheterization, Siracuse.
Background: Excimer laser coronary atherectomy (ELCA) is a technology used to treat a wide spectrum of complex coronary lesions, such as thrombotic lesions, severe calcific lesions, non-crossable or non-expandable lesions, chronic total occlusions, stent under-expansion, and stent restenosis.
Aims And Methods: This prospective multicenter observational study aims at examining procedural, in-hospital and long-term clinical outcomes in a consecutive cohort of patients treated with ELCA for complex coronary lesions. The primary end point was the rate of procedural success, defined as PCI success plus the absence of in-hospital MACE.
Lancet
April 2025
Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:
Background: Coronary artery calcification is common among patients undergoing percutaneous coronary intervention (PCI), and severe coronary artery lesion calcification is associated with increased procedural complexity, stent under-expansion, and high rates of intraprocedural complications and out-of-hospital adverse events. Whether calcium ablation before stent implantation can mitigate these adverse events is not currently established. We aimed to prospectively compare orbital atherectomy with a balloon angioplasty-based strategy before stent implantation for the treatment of severely calcified coronary lesions.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
June 2025
Department of Cardiology, Cardiovascular Institute, Thoraxcenter, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Background: Coronary calcification is a well-known marker of atherosclerotic plaque burden and a determinant of stent under expansion with unfavorable long-term outcomes.
Aims: This sub study of the randomized BIOVASC trial aimed to compare immediate complete revascularization (ICR) and staged complete revascularization (SCR) in patients with acute coronary syndrome (ACS) and multi vessel disease (MVD), stratified by calcification of the culprit lesion.
Methods: The primary endpoint consisted of a composite of all-cause mortality, myocardial infarction, unplanned ischemia driven revascularization (UIDR) and cerebrovascular events at 2 year follow-up.